JP2019535754A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535754A5 JP2019535754A5 JP2019527426A JP2019527426A JP2019535754A5 JP 2019535754 A5 JP2019535754 A5 JP 2019535754A5 JP 2019527426 A JP2019527426 A JP 2019527426A JP 2019527426 A JP2019527426 A JP 2019527426A JP 2019535754 A5 JP2019535754 A5 JP 2019535754A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound according
- compound
- pharmaceutically acceptable
- equation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(CCC(*(*)*)C(*(*)C(CCCC*(*)C(CCCc1ccc(*)cc1)=O)O)=O)=O Chemical compound CC(CCC(*(*)*)C(*(*)C(CCCC*(*)C(CCCc1ccc(*)cc1)=O)O)=O)=O 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662425810P | 2016-11-23 | 2016-11-23 | |
| US62/425,810 | 2016-11-23 | ||
| PCT/US2017/063182 WO2018098390A1 (en) | 2016-11-23 | 2017-11-24 | Albumin-binding psma inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535754A JP2019535754A (ja) | 2019-12-12 |
| JP2019535754A5 true JP2019535754A5 (enExample) | 2021-01-07 |
| JP7167021B2 JP7167021B2 (ja) | 2022-11-08 |
Family
ID=60812130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019527426A Active JP7167021B2 (ja) | 2016-11-23 | 2017-11-24 | アルブミン結合ｐｓｍａ阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11147889B2 (enExample) |
| EP (1) | EP3544960A1 (enExample) |
| JP (1) | JP7167021B2 (enExample) |
| CN (1) | CN109982998A (enExample) |
| BR (1) | BR112019010206A2 (enExample) |
| CA (1) | CA3043619A1 (enExample) |
| MX (1) | MX2019005742A (enExample) |
| WO (1) | WO2018098390A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3079906A1 (en) * | 2017-10-22 | 2019-04-25 | Provincial Health Services Authority | Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer |
| WO2019246445A1 (en) * | 2018-06-20 | 2019-12-26 | The Research Foundation For The State University Of New York | Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same |
| CA3118762A1 (en) | 2018-11-14 | 2020-05-22 | Noria Therapeutics, Inc. | Thioamide-containing compositions and methods of use thereof |
| WO2020108753A1 (en) * | 2018-11-28 | 2020-06-04 | ITM Isotopen Technologien München AG | Novel tumor antigen binding agents and uses thereof |
| CA3136979A1 (en) | 2019-04-17 | 2020-10-22 | Provincial Health Services Authority | Radiolabelled compounds for diagnosis or treatment of prostate-spe cific membrane antigen-expressing cancer |
| CN114401947B (zh) | 2019-06-21 | 2024-11-29 | 省卫生服务机构 | 靶向前列腺特异性膜抗原的放射性标记化合物 |
| WO2021177390A1 (ja) | 2020-03-04 | 2021-09-10 | 日本メジフィジックス株式会社 | 化合物及び放射性標識化合物 |
| MX2022013783A (es) * | 2020-05-06 | 2023-04-19 | Univ Cornell | Compuestos tratanosticos que contienen cobre y metodos de uso. |
| EP4255891A1 (en) * | 2020-12-04 | 2023-10-11 | The Regents of University of California | Peptide receptor radionuclide therapy |
| US20240018110A1 (en) * | 2020-12-16 | 2024-01-18 | The University Of British Columbia | Radiolabeled compounds targeting the prostate-specific membrane antigen |
| CN114685599A (zh) * | 2020-12-30 | 2022-07-01 | 南京江原安迪科正电子研究发展有限公司 | 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途 |
| JPWO2022186311A1 (enExample) * | 2021-03-04 | 2022-09-09 | ||
| CA3244865A1 (en) * | 2022-03-04 | 2023-09-07 | Provincial Health Services Authority | RADIOLABELLED COMPOUNDS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN |
| WO2024126687A1 (en) * | 2022-12-16 | 2024-06-20 | Silence Therapeutics Gmbh | Nucleic acids conjugated to an albumin binding moiety |
| CN118496305A (zh) * | 2023-02-16 | 2024-08-16 | 无锡诺宇医药科技有限公司 | Psma靶向放射性药物及其合成和应用 |
| CN116217505B (zh) * | 2023-03-17 | 2024-10-01 | 南京医科大学 | 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0621973D0 (en) * | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
| HRP20240952T1 (hr) * | 2009-03-19 | 2024-10-11 | The Johns Hopkins University | Spojevi koji ciljaju psma i njihova uporaba |
| PL2739316T3 (pl) * | 2011-08-05 | 2019-09-30 | Molecular Insight Pharmaceuticals, Inc. | Radioznakowane inhibitory antygenu błonowego specyficznego dla prostaty |
| US10011632B2 (en) * | 2011-08-22 | 2018-07-03 | Siemens Medical Solutions Usa, Inc. | PSMA imaging agents |
| US20160257961A1 (en) * | 2013-11-06 | 2016-09-08 | Solstice Biologics, Ltd. | Polynucleotide constructs having disulfide groups |
| BR112016010927A2 (pt) * | 2013-11-14 | 2017-08-08 | Endocyte Inc | Conjugado de fórmula |
| ES2912753T3 (es) * | 2014-08-24 | 2022-05-27 | Max Planck Gesellschaft Zur Foerderung Der Wss | Método para la producción de ésteres activos marcados con 18F y su aplicación ejemplificada por la preparación de un marcador de PET específico de PSMA |
| GEAP202014748A (en) * | 2015-09-30 | 2020-01-27 | Univ Heidelberg Ruprecht Karls | 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer |
| HUE065327T2 (hu) * | 2016-03-22 | 2024-05-28 | Univ Johns Hopkins | Prosztata-fajlagos membrán antigénhez célzott nagy affinitású szerek prosztatarák endoradioterápiájához |
| CA3028978A1 (en) * | 2016-06-23 | 2017-12-28 | Cornell University | Double targeted constructs to affect tumor kill |
| DE102016122273B4 (de) * | 2016-11-18 | 2018-06-21 | Abx Advanced Biochemical Compounds Gmbh | Präkursoren für die Radiofluorierung |
-
2017
- 2017-11-24 MX MX2019005742A patent/MX2019005742A/es unknown
- 2017-11-24 EP EP17821755.0A patent/EP3544960A1/en not_active Withdrawn
- 2017-11-24 WO PCT/US2017/063182 patent/WO2018098390A1/en not_active Ceased
- 2017-11-24 JP JP2019527426A patent/JP7167021B2/ja active Active
- 2017-11-24 BR BR112019010206A patent/BR112019010206A2/pt not_active Application Discontinuation
- 2017-11-24 US US16/349,756 patent/US11147889B2/en active Active
- 2017-11-24 CN CN201780071927.6A patent/CN109982998A/zh active Pending
- 2017-11-24 CA CA3043619A patent/CA3043619A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535754A5 (enExample) | ||
| CN101668547B (zh) | 选择缺氧组织的弱碱性2-硝基咪唑递送剂及其应用方法 | |
| US8435489B2 (en) | Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma | |
| EP1389209B1 (en) | Folate mimetics and folate-receptor binding conjugates thereof | |
| US11147889B2 (en) | Albumin-binding PSMA inhibitors | |
| US11541133B2 (en) | Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes | |
| JP2014510729A5 (enExample) | ||
| JP2006501149A5 (enExample) | ||
| RU2011146362A (ru) | Набор для предварительного таргетинга, способ и средства, используемые в нем | |
| JP2010523599A5 (enExample) | ||
| WO2008124651A3 (en) | Nitro-imidazole hypoxia imaging agents | |
| JP2010524965A5 (enExample) | ||
| JP2010511704A5 (enExample) | ||
| CA3030907A1 (en) | Chelated psma inhibitors | |
| DE602004017290D1 (de) | Konjugate für medizinische abbildungen umfassend träger, targeting-anteile und kontrastmittel | |
| JP2016528299A5 (enExample) | ||
| JP2012504131A5 (enExample) | ||
| CN111447955A (zh) | 99mTc-替马诺塞和相关的分子构建体用于鉴定和诊断恶性肿瘤和用于监测治疗性抗肿瘤干预的用途 | |
| CA2722858C (en) | Substrate based pet imaging agents | |
| JP2013504590A5 (enExample) | ||
| ES2616793T3 (es) | Derivados de quinoxalina marcados como productos radiofarmacéuticos multimodales y sus precursores | |
| JP2018502150A5 (enExample) | ||
| JP2009538894A5 (enExample) | ||
| Das et al. | 177Lu-DOTMP: a viable agent for palliative radiotherapy of painful bone metastasis | |
| Welch et al. | Production of non-standard PET radionuclides and the application of radiopharmaceuticals labeled with these nuclides |